Screener
Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — Gain (Loss) from Litigation Settlement
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GainLossRelatedToLitigationSettlement.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Intellectual property legal development expenses | 2,087 | 2,017 | 3,629 | 3,784 |
| Acquisition costs | 7,600 | — | 12,753 | — |
| Restructuring and other charges | 554 | 1,024 | 1,204 | 1,595 |
| Charges (credit) related to legal matters, net | 8,057 | (390) | 8,751 | (390) |
| Other operating income | (1,298) | — | (8,239) | (5,122) |
| Operating income | 129,769 | 111,372 | 271,541 | 211,719 |
| Other (expense) income: | ||||
| Interest expense, net | (55,043) | (65,101) | (108,404) | (122,040) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s affordable medicines — gain (loss) from litigation settlement?
- Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — gain (loss) from litigation settlement of -$8.06M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s affordable medicines — gain (loss) from litigation settlement changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s affordable medicines — gain (loss) from litigation settlement decreased by 2165.9% year-over-year, from $390K to -$8.06M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s affordable medicines — gain (loss) from litigation settlement?
- Over 2 years (2022 to 2024), Amneal Pharmaceuticals, Inc.'s affordable medicines — gain (loss) from litigation settlement has grown at a 107.8% compound annual growth rate (CAGR), from -$22.4M to -$96.69M.
- What does affordable medicines — gain (loss) from litigation settlement mean?
- Represents the net financial impact of legal settlements, judgments, or litigation-related awards recognized within the segment. This metric reflects non-recurring legal outcomes that can significantly impact segment profitability and operational cash flow.
Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — gain (loss) from litigation settlement.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude